ATELIER ACQ-CCC: NOUVEAUTÉS DANS LE DIAGNOSTIC ET LE TRAITEMENT DE LA MALADIE CORONARIENNE (CCC-154)

Saturday, October 28, 2023

08:30 – 09:15 EST

Location: Palais, 512AE

Target Audience: Clinical cardiologists, Community cardiologists, Trainee (clinical)

Chair(s)

Samer Mansour (he/him/his)

MD
CAIC
CHUM

Co-Chair(s)

Christine Pacheco, MD, MSc, FRCPC

Cardiologist
Hôpital Pierre-Boucher, Centre Hospitalier de l'Université de Montréal (CHUM)
Université de Montréal

Presenter(s)

Tomas Cieza, MD

Cardiologist
CCS
ICUPQ Université Laval
Guillaume Marquis-Gravel, MD, MSc

Interventional Cardiologist, Assistant Professor of Medicine
Montreal Heart Institute, Université de Montréal
Institut de Cardiologie de Montréal
Jean-Michel Paradis, MD

Interventional Cardiologist
Quebec Heart and Lung Institute
Laval University

Planning Committee Member(s)

Benoît M-Labbé, MD, MSc, FRCPC, FACC

Cardiologue échocardiographiste
Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ)
Université Laval
IN

Isabelle Nault Nault, MD, FRCPC (she/her/hers)

Cardiac Electrophysiologist
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Université Laval

Disclosure(s):

Samer Mansour: Abbott vascular: Consultant/Advisory Board (Terminated, April 2, 2023), Speaker/Honoraria (Terminated, April 2, 2023); Amgen: Consultant/Advisory Board (Terminated, April 2, 2023); Bayer: Speaker/Honoraria (Ongoing); Bohringer Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); HLS: Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Terminated, April 2, 2023), Speaker/Honoraria (Terminated, April 2, 2023); Sanofi: Consultant/Advisory Board (Terminated, April 2, 2023), Speaker/Honoraria (Terminated, April 2, 2023)

Christine Pacheco, MD, MSc, FRCPC: KYE pharmaceuticals: Consultant/Advisory Board (Terminated, January 6, 2022), Speaker/Honoraria (Terminated, January 6, 2022); Novartis: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Speaker/Honoraria (Ongoing)

Tomas Cieza, MD: No financial relationships to disclose

Guillaume Marquis-Gravel, MD, MSc: Bayer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, December 7, 2021), Speaker/Honoraria (Terminated, December 7, 2021); Boston Scientific: Consultant/Advisory Board (Terminated, May 12, 2022), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, May 12, 2022); CSI: Speaker/Honoraria (Terminated, April 26, 2022); HLS Therapeutics: Consultant/Advisory Board (Terminated); JAMP Pharma: Consultant/Advisory Board (Terminated, January 13, 2022), Speaker/Honoraria (Terminated, January 13, 2022); KYE: Consultant/Advisory Board (Terminated, May 11, 2022), Speaker/Honoraria (Terminated, May 11, 2022); Novartis: Consultant/Advisory Board (Terminated, March 22, 2023), Speaker/Honoraria (Terminated, March 22, 2023); Pharmascience: Consultant/Advisory Board (Terminated, April 14, 2022), Speaker/Honoraria (Terminated, April 14, 2022); Servier: Consultant/Advisory Board (Terminated, October 23, 2019)

Jean-Michel Paradis, MD: No financial relationships to disclose

Benoît M-Labbé, MD, MSc, FRCPC, FACC: No financial relationships to disclose

Isabelle Nault Nault, MD, FRCPC: Bayer: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing); Servier: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

plan coronary percutaneous intervention to perform dynamic invasive testing and to know the indication for such procedures;
cite indications to perform CTO (chronic total occlusion) procedures and describe expected results; and
describe advantages and disadvantages of invasive vs medical treatment for coronary heart disease.

Workshop Description: This workshop is intended to be presented in French, as part of the partnership with CCC and ACQ.
This workshop will fulfill the learning needs of those seeking a comprehensive overview of modern evaluation and treatment of coronrary heart disease. Clinical scenarios like those addressed in this workshop are a frequent challenge to all involved in the clinical management of patients. This workshop will provide participants with a comprehensive and practical approach to the use of invasive dynamic testing for coronary heart disease. It will also discuss in more detail patient selection for CTO interventions, indications of such procedures and clinical results to be expected after CTO disocclusion. Finally, it will provide participants an overview of medical vs invasive treatment strategy for coronary heart disease, to help decision making in the care of patients with ischemic heart disease.
The ACQ CME committee planned this workshop. Members of this committee include community and academic cardiologists, electrophysiologists and cardiology resident from diverse practices and experience across Quebec. The ACQ CME has developed an objective and balanced representation of the topic of "Atelier ACQ-CCC: Nouveautés dans le diagnostic et le traitement de la maladie coronarienne” that is completely free of third-party influence and/or support. Selected speakers from across Quebec are representative of diversity in gender, generation and practice.